LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

Home・Aandelen Lijst・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Gesloten

SectorGezondheidszorg

33.95 -5.14

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

32.81

Max

35.12

Belangrijke statistieken
By Trading Economics
Inkomsten	-5.8M 40M
Verkoop	16M 200M
K/W Sectorgemiddelde	11.9 35.733
EPS	0.92
Winstmarge	19.839
Werknemers	268
EBITDA	3M 59M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+41.86% upside

Dividenden
By Dow Jones
Volgende Winsten	28 okt 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	82M 2.1B
Vorige openingsprijs	39.09
Vorige sluitingsprijs	33.95

Nieuwssentiment

By Acuity

100%

147 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

29.8 / N/A Steun & Weerstand

Harmony Biosciences Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 sep 2025, 23:37 UTC

Populaire aandelen

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 sep 2025, 20:41 UTC

Winsten

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 sep 2025, 20:30 UTC

Winsten

GameStop 2Q Sales, Profit Rise

9 sep 2025, 23:19 UTC

Marktinformatie

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 sep 2025, 21:35 UTC

Winsten

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 sep 2025, 21:32 UTC

Winsten

Oracle's Backlog Swells With Big Customer Deals -- Update

9 sep 2025, 21:02 UTC

Acquisities, Fusies, Overnames

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 sep 2025, 20:33 UTC

Winsten

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 sep 2025, 20:26 UTC

Winsten

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sep 2025, 20:23 UTC

Winsten

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sep 2025, 20:12 UTC

Winsten

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 sep 2025, 20:10 UTC

Winsten

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 sep 2025, 20:10 UTC

Winsten

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 sep 2025, 20:09 UTC

Winsten

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 sep 2025, 20:09 UTC

Winsten

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 sep 2025, 20:08 UTC

Winsten

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 sep 2025, 20:08 UTC

Winsten

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 sep 2025, 20:08 UTC

Winsten

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 sep 2025, 20:08 UTC

Winsten

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 sep 2025, 20:07 UTC

Winsten

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 sep 2025, 20:06 UTC

Winsten

Oracle 1Q Software Revenue $5.72B >ORCL

9 sep 2025, 20:06 UTC

Winsten

Synopsys 3Q Adj EPS $3.39 >SNPS

9 sep 2025, 20:06 UTC

Winsten

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 sep 2025, 20:05 UTC

Winsten

Oracle 1Q Rev $14.93B >ORCL

9 sep 2025, 20:05 UTC

Winsten

Oracle 1Q EPS $1.01 >ORCL

9 sep 2025, 20:05 UTC

Winsten

Synopsys 3Q EPS $1.50 >SNPS

9 sep 2025, 20:05 UTC

Winsten

Oracle 1Q Services Revenue $1.35B >ORCL

9 sep 2025, 20:05 UTC

Winsten

Oracle 1Q Adj EPS $1.47 >ORCL

9 sep 2025, 20:05 UTC

Winsten

Oracle 1Q Hardware Revenue $670M >ORCL

Peer Vergelijking

Prijswijziging

Harmony Biosciences Holdings Inc Prognose

Koersdoel

By TipRanks

41.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 50.83 USD 41.86%

Hoogste 70 USD

Laagste 33 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Harmony Biosciences Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Harmony Biosciences Holdings Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

29.8 / N/ASteun & Weerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

147 / 371 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.